Beating both earnings and sales estimates typically generates positive investor sentiment, likely leading to a short-term increase in stock price. The significant outperformance in both key financial metrics indicates strong operational efficiency and market demand for Intra-Cellular Therapies' products, which could positively influence investor confidence and stock valuation in the short term.